Ikarian Capital’s NeuroSense Therapeutics NRSN Stock Holding History

Ikarian Capital’s Portfolio NRSN Stock Details NRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-100,000	Closed	-$397K	–	180
2022 Q1	$397K	Buy	+100,000	New	+$238K	0.05%	144

Other funds holding NRSN

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

VPIM

Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

Ikarian Capital's NRSN Position: Q2 2022 in Review

Ikarian Capital sold out of NeuroSense Therapeutics (NRSN) in Q2 2022, closing a stake of 100,000 shares — an estimated $397K sold.

Ikarian Capital first reported a position in NRSN in Q1 2022 and held it in 1 quarter. The position peaked at $397K in Q1 2022. 7 funds tracked by Wall St. Rank hold NRSN as of Q2 2022.

Ikarian Capital reported no remaining NeuroSense Therapeutics position as of Q2 2022 after selling out during the quarter.
Ikarian Capital sold 100,000 NeuroSense Therapeutics shares in Q2 2022, an estimated $397K.
Ikarian Capital first reported a position in NeuroSense Therapeutics in Q1 2022 and held it in 1 quarter.
Ikarian Capital's NeuroSense Therapeutics position peaked at $397K in Q1 2022.
7 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q2 2022.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.